Eletriptan Pfizer

Curr Opin Investig Drugs. 2002 Sep;3(9):1359-68.

Abstract

Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / statistics & numerical data
  • Drug Industry / legislation & jurisprudence
  • Drug Industry / methods*
  • Humans
  • Indoles / chemistry
  • Indoles / pharmacology*
  • Indoles / therapeutic use*
  • Pyrrolidines / chemistry
  • Pyrrolidines / pharmacology*
  • Pyrrolidines / therapeutic use*
  • Serotonin Receptor Agonists / pharmacology
  • Serotonin Receptor Agonists / therapeutic use
  • Tryptamines

Substances

  • Indoles
  • Pyrrolidines
  • Serotonin Receptor Agonists
  • Tryptamines
  • eletriptan